David S. Smith appointed to the Board of Directors of Predictive Oncology
October 25 2022 - 8:30AM
Predictive Oncology (NASDAQ: POAI) is pleased to announce the
appointment of David S. Smith, JD, to the company’s Board of
Directors.
Mr. Smith is a life sciences and corporate attorney, veteran
biotech industry executive and leading authority on the legal
issues surrounding the therapeutic use of human tissue and cells.
He has extensive transactional experience, venture financings and
regulatory matters for life sciences companies and investors.
“In the world of life sciences, specifically in terms of
intellectual property and the scientific and commercial use of
human tissue, David Smith is both a legal authority and a key
thought leader. His understanding of the value and significance of
our proprietary biorepository, especially with respect to the
biopharmaceutical industry, is unparalleled,” said Raymond F.
Vennare, Predictive Oncology’s chairman-elect who will be taking
over as CEO Nov. 1.
Mr. Smith frequently speaks on matters related to the commercial
development of tissue, cell and stem cell technologies, and has
authored extensively on topics like human tissue therapies and
tissue engineering research. His appointment to the board comes at
a time of growth anticipated for Predictive Oncology’s flagship
technology that pairs artificial intelligence with the world’s
largest commercial repository of tissue samples for oncology drug
discovery.
“We are at a turning point in drug discovery and I believe that
Predictive Oncology is leading the way. The variety of tissue
samples the company has is significant and unlike any other in the
marketplace. The way their scientists can introduce the molecule in
the environment, manipulate it and test how it will react provides
a new approach and great value to their clients,” explained Mr.
Smith.
Mr. Smith has been active in a number of trade organizations. He
currently serves on the Board of Directors of Foundation for Cell
and Gene Medicine. He is currently a Fellow and past member of the
executive committee of Tissue Engineering and Regenerative Medicine
International Society. He was additionally a member of the Board of
Directors of the Pennsylvania Biotechnology Association and past
officer of the Pittsburgh Tissue Engineering Initiative.
About Predictive OncologyPredictive Oncology
(NASDAQ: POAI) is a knowledge-driven company focused on applying
artificial intelligence (AI) to develop optimal cancer therapies,
which can lead to more effective treatments and improved patient
outcomes. Through AI, Predictive Oncology uses a biobank of
150,000+ cancer tumors, categorized by patient type, against drug
compounds to help the drug discovery process and increase the
probability of success. The company offers a suite of
solutions for oncology drug development from early discovery to
clinical trials.
Public Relations Contact:Predictive
OncologyTheresa Ferguson(630)
566-2003tferguson@predictive-oncology.com
Investor Relations Contact:Landon Capital Keith
Pinder(404) 995-6671kpinder@landoncapital.net
Forward-Looking Statements:Certain matters
discussed in this release contain forward-looking statements. These
forward-looking statements reflect our current expectations and
projections about future events and are subject to substantial
risks, uncertainties and assumptions about our operations and the
investments we make. All statements, other than statements of
historical facts, included in this press release regarding our
strategy, future operations, future financial position, future
revenue and financial performance, projected costs, prospects,
changes in management, plans and objectives of management are
forward-looking statements. The words “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target”
and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these identifying words. Our actual future performance may
materially differ from that contemplated by the forward-looking
statements as a result of a variety of factors including, among
other things, factors discussed under the heading “Risk Factors” in
our filings with the SEC. Except as expressly required by law,
the Company disclaims any intent or obligation to update these
forward-looking statements.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/c11cac53-e933-4fc4-b48c-4ac75f2e7759
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Sep 2023 to Sep 2024